ID   MKN1
AC   CVCL_1415
SY   MKN-1; MKN 1
DR   BTO; BTO:0002384
DR   CLO; CLO_0050804
DR   EFO; EFO_0002830
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473129
DR   BioSample; SAMN10987827
DR   cancercelllines; CVCL_1415
DR   Cell_Model_Passport; SIDM00271
DR   CGH-DB; 117-1
DR   CGH-DB; 9019-4
DR   ChEMBL-Cells; CHEMBL3307492
DR   ChEMBL-Targets; CHEMBL614352
DR   Cosmic; 733174
DR   Cosmic; 801337
DR   Cosmic; 848145
DR   Cosmic; 848379
DR   Cosmic; 887252
DR   Cosmic; 888824
DR   Cosmic; 897532
DR   Cosmic; 908138
DR   Cosmic; 922692
DR   Cosmic; 926111
DR   Cosmic; 1007600
DR   Cosmic; 1090459
DR   Cosmic; 1093296
DR   Cosmic; 1187282
DR   Cosmic; 1223586
DR   Cosmic; 1436023
DR   Cosmic; 1482076
DR   Cosmic; 1627263
DR   Cosmic; 1995508
DR   Cosmic; 2443801
DR   Cosmic; 2484957
DR   Cosmic; 2807632
DR   Cosmic-CLP; 908138
DR   DepMap; ACH-000351
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 908138
DR   GEO; GSM552363
DR   GEO; GSM562394
DR   GEO; GSM827531
DR   GEO; GSM844606
DR   GEO; GSM887323
DR   GEO; GSM888399
DR   GEO; GSM1374680
DR   GEO; GSM1670111
DR   IARC_TP53; 998
DR   JCRB; JCRB0252
DR   KCLB; 80101
DR   LiGeA; CCLE_128
DR   LINCS_LDP; LCL-1917
DR   Lonza; 1374
DR   PharmacoDB; MKN1_936_2019
DR   Progenetix; CVCL_1415
DR   PubChem_Cell_line; CVCL_1415
DR   RCB; RCB1003
DR   Wikidata; Q54905820
RX   CelloPub=CLPUB00581;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=758928;
RX   PubMed=1370612;
RX   PubMed=1778766;
RX   PubMed=1933850;
RX   PubMed=6862145;
RX   PubMed=9290701;
RX   PubMed=11107048;
RX   PubMed=15723654;
RX   PubMed=15767549;
RX   PubMed=15900046;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22336246;
RX   PubMed=22460905;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32847597;
RX   PubMed=34331011;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=MKN-1
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 43-45 hours (CelloPub=CLPUB00584).
CC   HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04; DQA1*04:01,04:01; DQB1*03:09,03:09; DRB1*11:01,03:17 (PubMed=25960936).
CC   HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Unspecified (PubMed=1370612; PubMed=11107048; PubMed=15900046).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.31%; Native American=0%; East Asian, North=81.4%; East Asian, South=15.4%; South Asian=0%; European, North=0.44%; European, South=2.44% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Cosmic-CLP; JCRB; KCLB; PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 10,12
ST   D16S539: 11,12
ST   D18S51: 13,16
ST   D21S11: 29
ST   D3S1358: 15,17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 20,23
ST   Penta D: 10
ST   Penta E: 21
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C5474; Gastric adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   CelloPub=CLPUB00581;
RA   Hojo H.;
RT   "Establishment of cultured cell lines of human stomach cancer origin
RT   and their morphological characteristics.";
RL   Niigata Igakkai Zasshi 91:737-763(1977).
//
RX   CelloPub=CLPUB00584;
RA   Motoya T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   PubMed=758928; DOI=10.1038/bjc.1979.3;
RA   Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y.,
RA   Yasumoto K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human cancer
RT   cell lines.";
RL   Br. J. Cancer 39:15-23(1979).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240;
RA   Naito S., Inoue S., Kinjo M., Tanaka K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human gastric
RT   cancer cell lines.";
RL   Gann 74:240-247(1983).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32847597; DOI=10.1186/s12943-020-01251-0;
RA   Kanda M., Shimizu D., Sawaki K., Nakamura S., Umeda S., Miwa T.,
RA   Tanaka H., Tanaka C., Hayashi M., Iguchi Y., Yamada S., Katsuno M.,
RA   Kodera Y.;
RT   "Therapeutic monoclonal antibody targeting of neuronal pentraxin
RT   receptor to control metastasis in gastric cancer.";
RL   Mol. Cancer 19:131.1-131.14(2020).
//
RX   PubMed=34331011; DOI=10.1038/s41388-021-01945-9;
RA   Kanda M., Shimizu D., Nakamura S., Sawaki K., Umeda S., Miwa T.,
RA   Tanaka H., Inokawa Y., Hattori N., Hayashi M., Tanaka C., Nakayama G.,
RA   Iguchi Y., Katsuno M., Kodera Y.;
RT   "Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody
RT   attenuates the aggressiveness of gastric cancer cells.";
RL   Oncogene 40:5495-5504(2021).
//